After the second dose of mRNA COVID-19 vaccine, breast milk levels of IgG(S1) increased and correlated with corresponding serum levels<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Aug. 25, 2021 (HealthDay News) — Breast milk from women vaccinated with the novel mRNA-based Pfizer-BioNTech COVID-19 vaccine contains specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig)G(S1) antibodies, according to a research letter published online Aug. 11 in JAMA Network Open<\/em>.<\/p>\n Erika Esteve-Palau, M.D., Ph.D., from Parc Sanitari Sant Joan de D \u00a9u in Barcelona, Spain, and colleagues characterized the levels of specific SARS-CoV-2 antibodies in the breast milk of 33 mRNA-vaccinated lactating women, as well as their correlation with serum antibody levels. <\/p>\n The researchers found that the median IgG(S1) levels for serum-milk pairs at the three time points were 519 to 1 arbitrary units (AU) per mL at two weeks after the first dose, 18,644 to 78 AU\/mL at two weeks after the second dose, and 12,478 to 50.4 AU\/mL at four weeks after the second dose. The Pearson correlation coefficient between breast milk and serum levels of IgG(S1) was 0.7.<\/p>\n “Larger prospective studies examining these issues are needed to confirm the safety of SARS-CoV-2 vaccination in individuals who are breastfeeding and further assess the association of vaccination with infants’ health and SARS-CoV-2-specific immunity,” the authors write.<\/p>\n